Roslin Technologies: Leading the Science of Sustainable Protein by Developing Tools for Cellular Agriculture

Roslin Technologies Limited（RTL）是一家领先的生物技术公司，旨在转变科学创新，为农业和动物健康领域的全球挑战提供解决方案。该公司是爱丁堡大学与两家拥有强大全球网络的投资合作伙伴的合资企业，总部位于世界上最大的动物科学创新中心之一的米德洛锡安科学区。RTL的工作方式是将来自学术界的突破性创新转化为实用的解决方案，帮助解决日益扩大的全球蛋白质缺口，从而提供支持更可持续的食品生产的产品和服务。为此，该公司拥有三个主要技术平台：创新育种计划、动物健康解决方案和动物细胞。后者包括最先进的技术，专门从事提取，生物银行，开发和培养动物干细胞。该平台的关键环节是动物诱导多能干细胞（iPS）的产生。这些是由成熟细胞产生的特殊类型的细胞，具有永生能力和分化成一系列靶细胞类型的能力。因此，iPS细胞可用于广泛的目的，包括干细胞治疗和现在的培养肉类生产。RTL的完全验证的、IP保护的用于牲畜和伴侣动物的iPS细胞系已被证明能够分化为一系列关键细胞类型（肌肉、脂肪、骨骼、软骨），为它们的潜在商业应用提供了证据。特别是，牲畜iPS细胞系显示出相当大的前景，为快速增长的全球细胞农业部门提供急需的资源。成功的早期工作已经在实验室规模上完成，该公司现在已经确定了几个商业细胞农业客户，其中一些人已经将RTL的猪iPS细胞系开发成培养肉原型。RTL现在准备大幅扩大这个iPS细胞平台，包括扩大其动物物种供应，并解决该行业的关键瓶颈步骤，例如可再生培养规模扩大，以实现具有成本效益的培养肉生产。该项目支持将RTL的iPS细胞平台技术带入下一阶段的关键步骤，在该阶段，该公司将准备为越来越多的国际养殖肉类公司提供服务，这些公司在过去2-3年中在蓬勃发展的细胞农业领域推出。

Roslin Technologies Limited (RTL) is a cutting-edge biotech company that aims to transform science innovations to provide solutions to global challenges in agriculture and animal health. The company, a joint venture between the University of Edinburgh and two investment partners with strong global networks, is based in the Midlothian Science Zone, one of the largest animal science innovation hubs in the world. This locale ensures that RTL is excellently placed to exploit ground-breaking innovations in the fields of animal science and biotechnology.The company's modus operandi is to translate ground-breaking innovations from academia to develop practical solutions that help address the increasing global protein gap and, in so doing, deliver products and services that support more sustainable food production. With this in mind, the company has three main technological platforms: Innovative Breeding Programmes, Animal Health Solutions and Animal Cells. The latter encompasses state-of-the-art technologies specialising in extracting, bio-banking, developing and cultivating animal stem cells. A key strand of this platform is the generation of animal induced pluripotent stem (iPS) cells. These are special types of cells, generated from mature cells, that have capacity for immortality and the ability to be differentiated into an array of target cell types. As such, iPS cells can be exploited for a wide range of purposes, including stem cell therapies and, now, cultured meat production.RTL's fully-validated, IP-protected iPS cell lines for livestock and companion animals have been shown to be capable of differentiation into a range of key cell types (muscle, fat, bone, cartilage), providing evidence of their potential commercial application. In particular, the livestock iPS cell lines show considerable promise to supply a much-needed resource for the rapidly-growing global Cellular Agriculture sector. Successful early work has been completed at laboratory scale and the company now has several commercial Cellular Agriculture clients identified, some of whom are already developing RTL's pig iPS cell lines into cultured meat prototypes. RTL is now poised to significantly scale up this iPS cell platform, including widening its animal species offering and tackling key bottleneck steps for the sector, such as reproducible culture scale-up for cost-effective cultured meat generation. This project supports the key steps in taking RTL's iPS cell platform technologies to the next stage in which the company will be poised to service the growing number of international cultured meat companies that have been launched in the flourishing Cellular Agriculture sector in the last 2-3 years.